Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease
NCT07459595Phase 1Not yet recruiting
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of myo-inositol in polycystic ovary syndrome (PCOS) (2 arms). Primary endpoints: Luteinizing Hormone to Follicle-Stimulating Hormone ratio at 3 months and Menstrual cycle regularity at 3 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
myo-inositol
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT07459595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459595.